Research Article
Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department
Table 3
Antibiotic resistance rates among 451 unique Enterobacteriaceae bacteria with and without multidrug resistance (MDR) isolated from 431 study patients.
| | Antibiotics | All isolates
() | MDR isolates
() | Non-MDR isolates
() | |
| | Ampicillin | 55% | 99% | 45% | <0.001 | | Amoxicillin-clavulanate | 10% | 35% | 4% | <0.001 | | Piperacillin-tazobactam | 2% | 9% | 1% | <0.001 | | Cefuroxime | 8% | 38% | 1% | <0.001 | | Ceftriaxone | 4% | 20% | 0% | <0.001 | | Cefepime | 3% | 17% | 0% | <0.001 | | Ertapenem | 0% | 0% | 0% | 1.00 | | Levofloxacin | 17% | 72% | 4% | <0.001 | | Gentamicin | 10% | 47% | 1% | <0.001 | | Amikacin | 1% | 2% | 0.3% | 0.10 | | Trimethoprim-sulfamethoxazole | 24% | 77% | 12% | <0.001 | | Nitrofurantoin | 14% | 21% | 12% | 0.04 | | ESBL resistance pattern | 5% | 24% | 0% | <0.001 |
|
|
aCompared between MDR and non-MDR isolates.
ESBL: extended-spectrum beta-lactamase.
|
